Evidence map›Paper›PMID 33596632›Full record

ArticleTurkish journal of haematology : official journal of Turkish Society of Haematology2021

Impact of Concomitant Aberrant CD200 and BCL2 Overexpression on Outcome of Acute Myeloid Leukemia: A Cohort Study from a Single Center

Mario Tiribelli, Angela Michelutti, Margherita Cavallin, Sara Di Giusto, Renato Fanin, Daniela Damiani

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Turkish journal of haematology : official journal of Turkish Society of Haematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Mario TiribelliUniversity of Udine, Department of Medical Area, Division of Hematology and Stem Cell Transplantation, Udine, ItalyORCID 0000-0001-9449-2621
Angela MicheluttiUniversity of Udine, Department of Medical Area, Division of Hematology and Stem Cell Transplantation, Udine, Italy
Margherita CavallinUniversity of Udine, Department of Medical Area, Division of Hematology and Stem Cell Transplantation, Udine, Italy
Sara Di GiustoUniversity of Udine, Department of Medical Area, Division of Hematology and Stem Cell Transplantation, Udine, Italy
Renato FaninUniversity of Udine, Department of Medical Area, Division of Hematology and Stem Cell Transplantation, Udine, Italy
Daniela DamianiUniversity of Udine, Department of Medical Area, Division of Hematology and Stem Cell Transplantation, Udine, ItalyORCID 0000-0002-1663-4468
University of Udine · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: CD200 and BCL2 overexpression is independently associated with inferior survival in acute myeloid leukemia (AML), and these two factors are frequently co-expressed; however, no data are available on the role of concomitant aberrant CD200 and BCL2 expression on outcome of AML patients. We aimed to elucidate the prognostic role of CD200/BCL2 co-expression and its association with specific leukemia subsets. Materials and Methods: We analyzed 242 adult AML patients uniformly treated with intensive chemotherapy, evaluating the impact of CD200 and BCL2 expression on complete remission (CR), disease-free survival, and overall survival (OS). Results: CD200 and BCL2 were expressed in 139 (57.4%) and 137 (56.6%) cases, respectively, with 92 patients (38%) displaying double positivity (DP), 58 (24%) displaying double negativity (DN), and 92 patients expressing only either CD200 (n=47) or BCL2 (n=45). CR was achieved in 71% of cases, being less frequent in DP patients (60%) compared to other groups (76%-81%, p<0.001). In the whole population 3-year OS was 44%, being lower in DP patients (28%) than in patients with single CD200 or BCL2 expression (47%) or DN cases (60%; p=0.004). Other factors associated with worse OS were advanced age, CD34 positivity, secondary AML, and high white blood cell count at diagnosis; combining these 4 factors with CD200/BCL2 DP, we identified 6 groups with significantly different rates of survival (3-year OS ranging from 90% to 0%). Conclusion: Our data support a synergistic effect of CD200 and BCL2 in AML cells, conferring an enhanced survival capacity in a permissive microenvironment and resulting in worse prognosis.

Indexed as

AdultAgedAged, 80 and overAntigens, CDCase-Control StudiesChromosome AberrationsCohort StudiesDisease-Free SurvivalDrug TherapyFemaleFlow CytometryGene ExpressionHumansLeukemia, Myeloid, AcuteMaleMiddle AgedAntigens, CDantigens, CD200BCL2 protein, humanProto-Oncogene Proteins c-bcl-2Acute myeloid leukemiaBCL2CD200PrognosisSurvival

Identifiers

PMID33596632
PMCPMC8171206
OpenAlexW3132308553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.